Condition: Articular Cartilage Defect · Articular Cartilage Degeneration · Sponsor: Biosolution Co., Ltd.
To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the subject with articular cartilage defects of the knee as a result of trauma or degeneration.
This description comes directly from the study's public registry record.
TaeKyung Kim, MA · +82234468884 · taekyung1215@biosolutions.co.kr
Jungsun Lee, Ph.D · +82234468884 · dvmljs@biosolutions.co.kr
Always discuss trial participation with your own doctor first.
| Tilda Research | Irvine, California, United States | Not Yet Recruiting |
| Biosolutions Clinical Research Center | La Mesa, California, United States | Recruiting |
| Horizon Clinical Research | La Mesa, California, United States | Recruiting |
| Lafayette General Health | Lafayette, Louisiana, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04744402